# Organoids & Organ-on-Chip: State of the Field (October 2026)

Research dossier · v1 · updated 2026-10-30 · 3,281 words · 61 sources · 25 claims · verification: verified

Covers stem-cell-derived and patient-derived organoids, fused assembloids and organ-on-chip platforms, and their use in disease modeling, drug testing and the 2025 regulatory shift away from animal testing. The main takeaway is that these systems are now routine research tools, but their predictive value for patient outcomes and their fidelity to adult tissue remain unproven for most uses.

## Contents

- Executive summary
- Background and core concepts
- Timeline of key milestones
- State of the art
  - Brain and neural organoids
  - Retina, heart, kidney, lung, liver and gut
  - Cancer organoids and drug testing
  - Organ-on-chip platforms
  - Quantitative benchmarks
- Open problems and active debates
- Major programs and players
- Outlook: what to watch (November 2026 to April 2028)
- Key papers
- Glossary

## Sample findings

- Organoids are three-dimensional, self-organizing cultures derived from pluripotent or adult stem cells that reproduce part of an organ's cell types and architecture.
- A 2020 study sequenced 285,441 single cells from human retinal organoids sampled at seven developmental time points and compared them with adult human retina.

## Get the full dossier

GET https://space-kitty.com/api/v1/dossiers/organoids costs $0.20 via x402 (USDC on Base Sepolia (testnet)). Send `Accept: text/markdown` for Markdown or `application/json` for structured data (claims with citations, timeline, benchmarks, open problems, glossary, bibliography).
---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.